X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
canagliflozin (464) 464
humans (450) 450
index medicus (427) 427
diabetes mellitus, type 2 - drug therapy (381) 381
hypoglycemic agents - therapeutic use (318) 318
diabetes (253) 253
type 2 diabetes (252) 252
glucose (231) 231
male (226) 226
sodium-glucose transporter 2 - antagonists & inhibitors (217) 217
female (207) 207
endocrinology & metabolism (205) 205
glucosides - therapeutic use (195) 195
dapagliflozin (192) 192
middle aged (186) 186
double-blind (179) 179
canagliflozin - therapeutic use (178) 178
safety (170) 170
hypoglycemic agents - adverse effects (156) 156
aged (144) 144
empagliflozin (142) 142
efficacy (135) 135
pharmacology & pharmacy (130) 130
sglt2 inhibitor (126) 126
dextrose (124) 124
diabetes mellitus, type 2 - blood (123) 123
metformin (123) 123
treatment outcome (123) 123
type 2 diabetes mellitus (123) 123
diabetes mellitus (121) 121
adult (112) 112
insulin (112) 112
benzhydryl compounds - therapeutic use (111) 111
thiophenes - therapeutic use (109) 109
glycemic control (107) 107
sodium (94) 94
blood glucose - metabolism (92) 92
blood glucose - drug effects (91) 91
glucosides - adverse effects (91) 91
hypoglycemic agents - administration & dosage (90) 90
mellitus (88) 88
medicine, general & internal (86) 86
body weight (85) 85
hypoglycemic agents - pharmacology (83) 83
care and treatment (82) 82
double-blind method (82) 82
blood pressure (80) 80
canagliflozin - adverse effects (80) 80
clinical trials (76) 76
internal medicine (76) 76
inadequate glycemic control (75) 75
analysis (73) 73
drug therapy (71) 71
sglt2 inhibitors (71) 71
sodium-glucose transporter 2 - metabolism (69) 69
diabetes mellitus, type 2 - metabolism (68) 68
drug therapy, combination (66) 66
glycated hemoglobin a - metabolism (66) 66
monotherapy (66) 66
sitagliptin (66) 66
diabetes therapy (64) 64
add-on (63) 63
animals (62) 62
hyperglycemia (61) 61
type-2 diabetes-mellitus (61) 61
risk factors (59) 59
hypoglycemic agents (58) 58
blood pressure - drug effects (57) 57
diabetes mellitus, type 2 - complications (57) 57
medicine & public health (56) 56
randomized controlled trials as topic (55) 55
hypoglycemia (54) 54
thiophenes - adverse effects (53) 53
glucosides - pharmacology (51) 51
cotransporter 2 inhibitor (50) 50
dose-response relationship, drug (50) 50
glucosides - administration & dosage (50) 50
hemoglobin (50) 50
patients (50) 50
canagliflozin - administration & dosage (49) 49
glycosylated hemoglobin (49) 49
canagliflozin - pharmacology (47) 47
hypoglycemia - chemically induced (47) 47
metformin - therapeutic use (47) 47
diabetes mellitus, type 2 - physiopathology (46) 46
glucose cotransporter 2 (46) 46
glucose transporter (46) 46
inhibitors (45) 45
benzhydryl compounds - adverse effects (44) 44
body weight - drug effects (44) 44
glucose metabolism (44) 44
endocrinology (40) 40
medical research (40) 40
risk (40) 40
abridged index medicus (39) 39
insulin resistance (39) 39
original (39) 39
research (39) 39
add-on therapy (38) 38
cardiovascular disease (38) 38
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Seminars in Nephrology, ISSN 0270-9295, 2016, Volume 36, Issue 6, pp. 436 - 447
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2016, Volume 18, Issue 8, pp. 783 - 794
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2015, Volume 17, Issue 6, pp. 581 - 590
Aims To assess the long‐term efficacy and tolerability of dapagliflozin versus glipizide as add‐on to metformin in patients with inadequately controlled type 2... 
type 2 diabetes | SGLT2 inhibitor | dapagliflozin | safety | efficacy | durability | Type 2 diabetes | Durability | Efficacy | Safety | Dapagliflozin | URINARY-TRACT-INFECTIONS | MELLITUS | RANDOMIZED CLINICAL-TRIALS | BODY-WEIGHT | HYPERGLYCEMIA | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | COTRANSPORTER 2 INHIBITOR | PLACEBO-CONTROLLED TRIAL | EMPAGLIFLOZIN | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Double-Blind Method | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Male | Treatment Outcome | Glipizide - therapeutic use | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Drug Therapy, Combination - methods | Glomerular Filtration Rate - drug effects | Urinary Tract Infections - chemically induced | Female | Glucosides - therapeutic use | Aged | Blood Pressure - drug effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Care and treatment | Analysis | Urinary tract infections | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Confidence intervals | Medical research | Diabetes | Diabetes mellitus | Body weight | Blood pressure | Urinary tract | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent)
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 10/2017, Volume 333, pp. 43 - 50
Dipeptidyl peptidase-4 inhibitor (vildagliptin) has been shown to exert beneficial effects on insulin sensitivity and neuroprotection in obese-insulin... 
Obese-insulin resistance | Vildagliptin | Cognitive function | Mitochondrial function | Dapagliflozin | Synaptic plasticity | METFORMIN | HOMEOSTASIS | COGNITION | DENSITY | PLASMA | CANAGLIFLOZIN | GLUCOSE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | RECEPTOR FUNCTION | Memory - drug effects | Neuroprotective Agents - therapeutic use | Reactive Oxygen Species - metabolism | Insulin - physiology | Nitriles - pharmacology | Obesity - drug therapy | Rats, Wistar | Apoptosis - drug effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Cognition Disorders - metabolism | Male | Membrane Potential, Mitochondrial - drug effects | Brain - physiology | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Brain - metabolism | Neuroprotective Agents - pharmacology | Long-Term Potentiation - drug effects | Diet, High-Fat | Malondialdehyde - blood | Adamantane - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Adamantane - analogs & derivatives | Malondialdehyde - metabolism | Adamantane - pharmacology | Cognition Disorders - physiopathology | Glucosides - pharmacology | Anti-Inflammatory Agents - pharmacology | Insulin Resistance | Obesity - physiopathology | Mitochondria - metabolism | Mitochondria - drug effects | Cognition Disorders - drug therapy | Maze Learning - drug effects | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Obesity - metabolism | Brain - drug effects | Animals | Benzhydryl Compounds - pharmacology | Oxidative Stress - drug effects | Mitochondria - physiology | Nitriles - therapeutic use | Obesity | Brain | Insulin resistance | Apoptosis | Analysis and chemistry | Low density lipoproteins | Cognition disorders | Glucose tolerance tests | Blood | High performance liquid chromatography | Neurophysiology | Index Medicus | INSULIN | APOPTOSIS | DRUGS | MITOCHONDRIA | RATS | SENSITIVITY | METABOLIC DISEASES | 60 APPLIED LIFE SCIENCES | BRAIN
Journal Article